Gary McLean is an Honorary Research Fellow in the Airway Disease Infection Section of the National Heart and Lung Institute.
His prior research on blood cell development, immune responses to human viral pathogens and molecular studies of antibody generation were performed in North America.
Currently his research investigates immune responses to rhinovirus infections and the role of microvesicles in the spread of respiratory viral infections - the aim of his research is to generate novel therapeutic interventions or a protective vaccine to rhinovirus.
et al., 2024, Antivirals for Broader Coverage against Human Coronaviruses., Viruses, Vol:16
et al., 2023, A temperature-dependent virus-binding assay reveals the presence of neutralizing antibodies in human cytomegalovirus gB vaccine recipients' sera, Journal of General Virology, Vol:104, ISSN:0022-1317
et al., 2022, Rapid Quantification of SARS-CoV-2 Neutralising Antibodies Using Time-Resolved Fluorescence Immunoassay, Vaccines, Vol:10
et al., 2022, The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines, Mbio, Vol:13, ISSN:2150-7511
et al., 2022, Two pandemics in China, One Health in Chinese, Bmj Global Health, Vol:7, ISSN:2059-7908